
14. The compound having the Formula



15. A method of treating cardiovascular conditions comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug.

16. A method as recited in claim 15 wherein the cardiovascular condition is heart failure, congestive heart failure, peripheral arterial disease, pulmonary hypertension or vasculitis.

17. A method as recited in claim 15 wherein the mammal has unstable angina or has experienced myocardial infarction.

18. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent.

19. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;

a second compound, said second compound being an angiotensin converting enzyme inhibitor, a HMG-CoA reductase inhibitor, a non-steroidal anti-inflammatory agent, a Factor Xa inhibitor or warfarin; and

a pharmaceutical carrier, vehicle or diluents.

20. The compound of claim 4 wherein

R^1 is naphthyl, quinolinyl, isoquinolinyl, indolyl, benzo[b]thiophenyl, benzothiazolyl, benzo[b]furanyl or thiophenyl and said R^1 is mono-, di-, or tri-substituted independently with hydroxyethoxy, methyl, methoxy, fluoro or chloro; and

R^2 is diaminomethyleneamino(C_2-C_4)alkyl, carbamoyl(C_1-C_4)alkyl, hydroxy(C_2-C_4)alkyl, amino(C_2-C_4)alkylcarbamoyl(C_1-C_4)alkyl, (C_1-C_4)alkylcarbonylamino(C_2-C_4)alkyl, amino(C_1-C_4)alkylcarbonylamino(C_2-C_4)alkyl, amino(C_3-C_4)hydroxyalkyl or amino(C_2-C_4)alkyl.

21. The compound or a pharmaceutically acceptable salt thereof wherein the compound is


2-[6-(2,4-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide;
2-[6-(2-methoxy-5-methylphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide;
1-[(2R)-2-aminopropyl]-6-(2,4-dimethoxyphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one;
2-[6-(3-methoxy-2-naphthyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide; or
2-[6-(1H-indol-4-yl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide.

22. The compound or a pharmaceutically acceptable salt thereof wherein the compound is


2-{6-[2-(2-hydroxyethoxy)-5-methoxyphenyl]-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl}acetamide;
N-(2-aminoethyl)-2-{6-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl}acetamide;
6-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-1-(2-hydroxyethyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one;
6-[5-fluoro-2-(2-hydroxyethoxy)phenyl]-1-(2-hydroxyethyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; or
2-{6-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl}acetamide.

23. The compound N-(2-aminoethyl)-2-[6-(2,4-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide or a pharmaceutically acceptable salt thereof.

24. The compound having the Formula



25. A compound having Formula I A



Formula I A

or a pharmaceutically acceptable salt or prodrug thereof

wherein

R^1 is a five to six membered aromatic ring optionally having one to three heteroatoms selected independently from nitrogen, sulfur and oxygen or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated five to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen; and

said R^1 is optionally mono-, di-, or tri-substituted independently with cyano, halo, hydroxyl, amino, $(C_1$-$C_4)$alkyl, $(C_1$-$C_4)$alkoxy, $(C_1$-$C_4)$alkoxy$(C_1$-$C_4)$alkyl, hydroxy$(C_2$-$C_4)$alkoxy, carbamoyl$(C_1$-$C_4)$alkoxy, amino$(C_2$-$C_4)$alkoxy, cyano$(C_1$-$C_4)$alkyl, $(C_1$-$C_4)$alkylcarbonyloxy$(C_1$-$C_4)$alkyl, amino$(C_1$-$C_4)$alkylcarbonyloxy$(C_1$-$C_4)$alkyl, $(C_1$-$C_4)$alkylcarbonyloxy$(C_1$-$C_4)$alkoxy, amino$(C_1$-$C_4)$alkylcarbonyloxy$(C_1$-$C_4)$alkoxy, mono-N- or di-N,N-$(C_1$-$C_4)$alkylamino, aminocarbonyl, mono-N- or di-N,N$(C_1$-$C_4)$alkylaminocarbonyl, $(C_1$-$C_4)$alkylthio, aminosulfonyl, $(C_1$-$C_4)$alkylsulfinyl, $(C_1$-

C_4)alkylsulfonyl, or mono-N- or di-N,N(C_1-C_4)alkylaminosulfonyl, wherein any of the (C_1-C_4)alkyl or (C_1-C_4)alkoxy may be optionally mono-, di- or tri-substituted with fluoro; or wherein R^1 is optionally substituted with a five to six membered aromatic ring optionally having one to three heteroatoms selected independently from nitrogen, sulfur and oxygen;

R^2 is a fully saturated, partially unsaturated or fully unsaturated one to fourteen membered straight carbon chain wherein the carbons, other than the connecting carbon,

a. may be branched

b. may optionally be replaced with one or two heteroatoms selected independently from oxygen and sulfur and may optionally be replaced with one to four nitrogens, wherein said sulfur is optionally mono- or di-substituted with oxo,

c. may optionally be mono-, di- or tri-substituted independently with halo,

d. may optionally be mono-substituted with hydroxy, and

e. may optionally be mono-substituted with oxo,

and wherein the carbon chain is optionally mono-substituted with Z;

wherein Z is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated five to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z is optionally mono-, di- or tri-substituted independently with amino, halo, (C_1-C_6)alkyl, (C_1-C_6)alkylcarbonyl, aminothioxo, amino(C_1-C_6)alkylcarbonyl, hydroxyl, diaminomethylene, carbamoyl or (C_1-C_6)alkoxy and wherein said (C_1-C_6)alkyl or (C_1-C_6)alkoxy substituent is also optionally substituted with one to three halo, and wherein said (C_1-C_6)alkyl or (C_2-C_6)alkoxy substituent is also optionally substituted with one to three hydroxy;

with the proviso that R^1 is not unsubstituted phenyl, and R^2 is not unsubstituted(C_1-C_6)alkyl.

26. A method for treating cardiovascular events and conditions comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 25 or a prodrug thereof or a pharmaceutically acceptable salt of

said compound or of said prodrug wherein the cardiovascular condition or event is heart failure, congestive heart failure, peripheral arterial disease, pulmonary hypertension, vasculitis, a primary or secondary myocardial infarction, ischemia, ischemia reperfusion injury, atrial fibrillation or coronary artery bypass graft surgery.

27. A method of treating a condition comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 25 or a prodrug thereof or a pharmaceutically acceptable salt of said compound of said prodrug wherein the condition is dialysis, delayed graft function, transplant organ rejection or nephropathy caused by contrasting agents

28. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 25 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent.


29. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 25, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;

a second compound, said second compound being an angiotensin converting enzyme inhibitor, a HMG-CoA reductase inhibitor, a non-steroidal anti-inflammatory agent, a Factor Xa inhibitor or warfarin; and

a pharmaceutical carrier, vehicle or diluents.

14. The compound having the Formula



15. A compound of claim 1 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug, for use in the treatment of cardiovascular conditions.

16. The compound as recited in claim 15 wherein the cardiovascular condition is heart failure, congestive heart failure, peripheral arterial disease, pulmonary hypertension or vasculitis.

17. The compound as recited in claim 15 wherein the mammal has unstable angina or has experienced myocardial infarction.

18. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent.

19. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;

a second compound, said second compound being an angiotensin converting enzyme inhibitor, a HMG-CoA reductase inhibitor, a non-steroidal anti-inflammatory agent, a Factor Xa inhibitor or warfarin; and

a pharmaceutical carrier, vehicle or diluents.

20. The compound of claim 4 wherein

R^1 is naphthyl, quinolinyl, isoquinolinyl, indolyl, benzo[b]thiophenyl, benzothiazolyl, benzo[b]furanyl or thiophenyl and said R^1 is mono-, di-, or tri-substituted independently with hydroxyethoxy, methyl, methoxy, fluoro or chloro; and

R^2 is diaminomethyleneamino(C_2-C_4)alkyl, carbamoyl(C_1-C_4)alkyl, hydroxy(C_2-C_4)alkyl, amino(C_2-C_4)alkylcarbamoyl(C_1-C_4)alkyl, (C_1-C_4)alkylcarbonylamino(C_2-C_4)alkyl, amino(C_1-C_4)alkylcarbonylamino(C_2-C_4)alkyl, amino(C_3-C_4)hydroxyalkyl or amino(C_2-C_4)alkyl.

21. The compound or a pharmaceutically acceptable salt thereof wherein the compound is


2-[6-(2,4-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide;
2-[6-(2-methoxy-5-methylphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide;
1-[(2R)-2-aminopropyl]-6-(2,4-dimethoxyphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one;
2-[6-(3-methoxy-2-naphthyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide; or
2-[6-(1H-indol-4-yl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide.

22. The compound or a pharmaceutically acceptable salt thereof wherein the compound is
2-{6-[2-(2-hydroxyethoxy)-5-methoxyphenyl]-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl}acetamide;
N-(2-aminoethyl)-2-{6-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl}acetamide;
6-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-1-(2-hydroxyethyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one;


6-[5-fluoro-2-(2-hydroxyethoxy)phenyl]-1-(2-hydroxyethyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; or
2-{6-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl}acetamide.

23. The compound
N-(2-aminoethyl)-2-[6-(2,4-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide or a pharmaceutically acceptable salt thereof.

24. The compound having the Formula



25. A compound having Formula I A



Formula I A

or a pharmaceutically acceptable salt or prodrug thereof
wherein
R^1 is a five to six membered aromatic ring optionally having one to three heteroatoms selected independently from nitrogen, sulfur and oxygen or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated five to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen; and

said R^1 is optionally mono-, di-, or tri-substituted independently with cyano, halo, hydroxyl, amino, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)alkoxy(C_1-C_4)alkyl, hydroxy(C_2-C_4)alkoxy, carbamoyl(C_1-C_4)alkoxy, amino(C_2-C_4)alkoxy, cyano(C_1-C_4)alkyl, (C_1-C_4)alkylcarbonyloxy(C_1-C_4)alkyl, amino(C_1-C_4)alkylcarbonyloxy(C_1-C_4)alkyl, (C_1-C_4)alkylcarbonyloxy(C_1-C_4)alkoxy, amino(C_1-C_4)alkylcarbonyloxy(C_1-C_4)alkoxy, mono-N- or di-N,N-(C_1-C_4)alkylamino, aminocarbonyl, mono-N- or di-N,N(C_1-C_4)alkylaminocarbonyl, (C_1-C_4)alkylthio, aminosulfonyl, (C_1-C_4)alkylsulfinyl, (C_1-C_4)alkylsulfonyl, or mono-N- or di-N,N(C_1-C_4)alkylaminosulfonyl, wherein any of the (C_1-C_4)alkyl or (C_1-C_4)alkoxy may be optionally mono-, di- or tri-substituted with fluoro; or wherein R^1 is optionally substituted with a five to six membered aromatic ring optionally having one to three heteroatoms selected independently from nitrogen, sulfur and oxygen;

R^2 is a fully saturated, partially unsaturated or fully unsaturated one to fourteen membered straight carbon chain wherein the carbons, other than the connecting carbon,

a. may be branched

b. may optionally be replaced with one or two heteroatoms selected independently from oxygen and sulfur and may optionally be replaced with one to four nitrogens, wherein said sulfur is optionally mono- or di-substituted with oxo,

c. may optionally be mono-, di- or tri-substituted independently with halo,

d. may optionally be mono-substituted with hydroxy, and

e. may optionally be mono-substituted with oxo,

and wherein the carbon chain is optionally mono-substituted with Z;

wherein Z is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated five to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z is optionally mono-, di- or tri-substituted independently with amino, halo, (C_1-C_6)alkyl, (C_1-C_6)alkylcarbonyl, aminothioxo, amino(C_1-C_6)alkylcarbonyl, hydroxyl, diaminomethylene, carbamoyl or (C_1-C_6)alkoxy

and wherein said (C_1-C_6)alkyl or (C_1-C_6)alkoxy substituent is also optionally substituted with one to three halo, and wherein said (C_1-C_6)alkyl or (C_2-C_6)alkoxy substituent is also optionally substituted with one to three hydroxy; with the proviso that R^1 is not unsubstituted phenyl, and R^2 is not unsubstituted(C_1-C_6)alkyl.

26. A compound of claim 25 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug, for use in the treatment of cardiovascular events and conditions, wherein the cardiovascular condition or event is heart failure, congestive heart failure, peripheral arterial disease, pulmonary hypertension, vasculitis, a primary or secondary myocardial infarction, ishcemia, ischemia reperfusion injury, atrial fibrillation or coronary artery bypass graft surgery.

27. A compound of claim 25 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug, for use in the treatment of a condition, wherein the condition is dialysis, delayed graft function, transplant organ rejection or nephropathy caused by contrasting agents.

28. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 25 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent.

29. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 25, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;

a second compound, said second compound being an angiotensin converting enzyme inhibitor, a HMG-CoA reductase inhibitor, a non-steroidal anti-inflammatory agent, a Factor Xa inhibitor or warfarin; and

a pharmaceutical carrier, vehicle or diluents.